Bionote launches new Equine panels, eProgesterone and eSAA

Bionote, a leading veterinary diagnostic company based in Korea, is introducing two new biomarkers, eProgesterone and eSAA, as a part of the Vcheck series.    Vcheck eProgesterone is an in vitro diagnostic test kit for the quantitative measurement of progesterone concentration in Equine serum and plasma. This test kit precisely quantifies the degree of elevation in progesterone levels in horses.    Progesterone plays a crucial role in the maintenance of pregnancy until 120 days of gestation when the placenta becomes the main source. In addition, measuring progesterone helps find out mare’s reproductive cycle and plan most effectively. Vcheck eProgesterone assay allows you to quickly analyze Equine progesterone in the field, evaluate corpus callosum in the early stages of pregnancy, and monitor progesterone during pregnancy. Vcheck eProgesterone: This one-step test procedure is easy to follow and provides fast results within 15 minutes using serum and plasma samples from horses.   Vcheck Equine SAA is an in vitro diagnostic test kit for the quantitative measurement of SAA concentration in Equine serum and plasma. This test kit precisely quantifies the degree of elevation in SAA levels in horses.   SAA concentration increases in response to several clinical conditions in horses, such as sepsis, viral infections, arthritis, gastrointestinal and reproductive disease. Also, its measurement is useful for monitoring the response to treatment. Vcheck Equine SAA assay allows early detection of the presence of inflammation, monitors the post-operative effects and recovery, and serial monitoring of the response to treatment. Vcheck Equine SAA: This one-step test procedure is easy to follow and provides fast results within 5 minutes using serum and plasma samples from horses.   Bionote will also be introducing Vcheck Foal IgG within the first half of 2023. If you are interested in Vcheck eProgesterone and/or Vcheck Equine SAA, please contact your local distributor or mail to [bionote@bionote.co.kr].  

• 2023.03.27
• Hits : 2,665

Bionote Redoubles Efforts to Expand Further into the US Market

 DISCLAIMER: This news article is a direct translation of the original Korean article from Pharm News. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.- ​Bionote USA attends 'WVC 2023', the largest veterinary conference held in the US- ​Focus on Veterinary Diagnostic Analyzers such as Vcheck F and Vcheck MLeading global biological raw material and animal diagnostics company BIONOTE is continuing its efforts to expand further into the US market.Bionote announced on the 28th, that its US Branch, BIONOTE USA (established in 2019), participated in the 'Western Veterinary Conference 2023' ("WVC") held in Las Vegas, NV, from the 19th of February to the 22nd of February and carried out extensive promotional and marketing activities.WVC is the largest veterinary conference, in terms of scale, held in the US and veterinary experts as well as companies from around the world meet to share their insight, latest innovations in animal related products/services.According to Bionote, their US counterpart actively promoted their Vcheck F immunodiagnostic analyzers (V200, V2400), as well as the newly developed equine progesterone, SAA and IgG biomarkers, at the event.Furthermore, BIONOTE USA also promoted the newly released POC molecular diagnostic analyzer, Vcheck M, which is capable of nucleic acid amplification and quantitative analysis for the detection and diagnosis of major infectious diseases. Vcheck M is intuitive to use, even without much training, for performing PCR on site with the results being ready within only 1 hour, explained Bionote.A Bionote spokesperson said, "We plan on continuing our marketing and promotional activities in future conferences and events" and that "Bionote will continue to expand our market share by introducing our molecular diagnostic products and clinical chemistry products along with our usual immunodiagnostic products, showcasing our diverse product portfolio to the global market".Link to original article: https://www.pharmnews.com/news/articleView.html?idxno=219272

• 2023.03.02
• Hits : 101,926

Bionote, strategically invests in Centenaire Biosciences... initiating business diversification in earnest

- Carried out 16.5 million USD capital investment in addition to the 7.8 million USD invested last year - Business diversification through joint development of therapeutic antibody    Bionote announced on the 8th of February, that they have entered into a contract with therapeutic antibody development company, Centenaire Biosciences ("Centenaire"), through which Bionote invested 16.5 million USD as capital investment.   The total investment amount amounts to 24.3 million USD, including the 7.8 million USD invested last year along with SD Investment. The total share held increased from 9.09% to 27%. Bionote plans to continue their ongoing partnership with Centenaire through this investment, especially in co-developing new therapeutic antibody pipelines.   Centenaire is a sister company of Meditox, founded in 2021. They have been developing treatments for cancer, autoimmune diseases, and nervous system diseases through their innovative antibody platform technology. CTN001, which has been shown to be greatly effective for HER2 low-expression cancer has especially great market potential as the HER2 accounts for over 50% of breast cancers.   The two companies are planning for the clinical trials of the CTN001 product, signing a contract with Samsung Biologics and developing the process for the manufacture of clinical samples. Furthermore, the two companies are also cooperating in the development of new treatments for non-small cell lung cancer and acute myeloid leukemia as well as cancer immunotherapy amongst various next generation anti-cancer treatments, expanding their research further.   Dr. Byung Ki Cho, CEO of Bionote, commented that "We will strive to develop new, revolutionary therapeutic antibodies through our unrivaled antibody, antigen technology, coupled with the R&D capabilities of our company, which will synergize with Centenaire's innovative antibody platform technology". Ki Hyeok Yang, CEO of Centenaire, also commented that they would like to "Thank Bionote for trusting in the technology and development capabilities of Centenaire, continuing to invest large amounts in both 2022 and 2023." and added that "Centenaire will grow to be a game changer in the market by continuing to develop our own, original, products through our antibody platform technology, in a market full of new innovation, such as cancer immunotherapy, antibody-drug conjugates and T-cell engagers. 

• 2023.02.08
• Hits : 4,840